1. Home
  2. VIRT vs LQDA Comparison

VIRT vs LQDA Comparison

Compare VIRT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtu Financial Inc.

VIRT

Virtu Financial Inc.

HOLD

Current Price

$36.90

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$37.31

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIRT
LQDA
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.1B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
VIRT
LQDA
Price
$36.90
$37.31
Analyst Decision
Hold
Strong Buy
Analyst Count
7
10
Target Price
$42.29
$38.60
AVG Volume (30 Days)
1.0M
1.9M
Earning Date
01-29-2026
11-03-2025
Dividend Yield
2.60%
N/A
EPS Growth
132.69
N/A
EPS
4.62
N/A
Revenue
$2,694,104,000.00
$69,216,000.00
Revenue This Year
N/A
$1,005.03
Revenue Next Year
N/A
$204.13
P/E Ratio
$7.99
N/A
Revenue Growth
41.05
343.41
52 Week Low
$31.55
$11.26
52 Week High
$45.77
$41.57

Technical Indicators

Market Signals
Indicator
VIRT
LQDA
Relative Strength Index (RSI) 68.10 60.22
Support Level $33.24 $29.41
Resistance Level $34.28 $41.57
Average True Range (ATR) 1.02 3.03
MACD 0.40 0.43
Stochastic Oscillator 93.27 68.38

Price Performance

Historical Comparison
VIRT
LQDA

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: